New hope for Hard-to-Treat cancers: first human trial launches
NCT ID NCT05277051
First seen Nov 11, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This early-stage study tests a new drug called remzistotug in 152 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to check the drug's safety and how the body processes it, both alone and with other cancer drugs. Participants must have certain types of tumors and meet specific health criteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
San Francisco, California, 94158, United States
-
GSK Investigational Site
Charlotte, North Carolina, 28204, United States
-
GSK Investigational Site
Oklahoma City, Oklahoma, 73104, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19111, United States
-
GSK Investigational Site
Dallas, Texas, 75230, United States
-
GSK Investigational Site
San Antonio, Texas, 78229, United States
-
GSK Investigational Site
Salt Lake City, Utah, 84112, United States
-
GSK Investigational Site
Nedlands, Western Australia, 6009, Australia
-
GSK Investigational Site
Ottawa, Ontario, K1H 8L6, Canada
-
GSK Investigational Site
Toronto, Ontario, M5G 2M9, Canada
-
GSK Investigational Site
Chengdu, 610041, China
-
GSK Investigational Site
Jinan, 250117, China
-
GSK Investigational Site
Shanghai, 200126, China
-
GSK Investigational Site
Wuhan, 430022, China
-
GSK Investigational Site
Dijon, 21000, France
-
GSK Investigational Site
Lille, 59000, France
-
GSK Investigational Site
Chiba, 277-8577, Japan
-
GSK Investigational Site
Tokyo, 104-0045, Japan
-
GSK Investigational Site
Seoul, 03080, South Korea
-
GSK Investigational Site
Seoul, 03722, South Korea
-
GSK Investigational Site
Barcelona, 08035, Spain
-
GSK Investigational Site
Madrid, 28040, Spain
-
GSK Investigational Site
Madrid, 28050, Spain
-
GSK Investigational Site
Málaga, 29010, Spain
-
GSK Investigational Site
Manchester, M20 4BX, United Kingdom
-
GSK Investigational Site
Sutton, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.